BioInvent to Show Further Positive BI-1206 Clinical Data in December at ASH 2021

BI-1206 restores rituximab activity in relapsed or refractory patientsDemonstrates ORR 50%, DCR 58%, with complete responses lasting beyond 18 and 24 monthsLUND, SE / ACCESSWIRE / November 4, 2021 / BioInvent International AB ("BioInvent") …